Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems. The Company’s drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. The Company’s portfolio consists of product candidates, such as Epoladerm, Probudur, Envelta, PES200, AnQlar, and VRP324. Epoladerm is a daily topical nonsteroidal anti-inflammatory drug (NSAID) use to treat chronic osteoarthritis of the knee. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. AnQlar also demonstrated reduced brain viral load in the in-vivo study. VRP324 is being developed to treat seizures associated with Dravet and Lennox-Gastaut Syndromes in patients two years and older.